301 related articles for article (PubMed ID: 20847202)
1. Gene therapy augments the efficacy of hematopoietic cell transplantation and fully corrects mucopolysaccharidosis type I phenotype in the mouse model.
Visigalli I; Delai S; Politi LS; Di Domenico C; Cerri F; Mrak E; D'Isa R; Ungaro D; Stok M; Sanvito F; Mariani E; Staszewsky L; Godi C; Russo I; Cecere F; Del Carro U; Rubinacci A; Brambilla R; Quattrini A; Di Natale P; Ponder K; Naldini L; Biffi A
Blood; 2010 Dec; 116(24):5130-9. PubMed ID: 20847202
[TBL] [Abstract][Full Text] [Related]
2. Normalization and improvement of CNS deficits in mice with Hurler syndrome after long-term peripheral delivery of BBB-targeted iduronidase.
El-Amouri SS; Dai M; Han JF; Brady RO; Pan D
Mol Ther; 2014 Dec; 22(12):2028-2037. PubMed ID: 25088464
[TBL] [Abstract][Full Text] [Related]
3. Targeting a Pre-existing Anti-transgene T Cell Response for Effective Gene Therapy of MPS-I in the Mouse Model of the Disease.
Squeri G; Passerini L; Ferro F; Laudisa C; Tomasoni D; Deodato F; Donati MA; Gasperini S; Aiuti A; Bernardo ME; Gentner B; Naldini L; Annoni A; Biffi A; Gregori S
Mol Ther; 2019 Jul; 27(7):1215-1227. PubMed ID: 31060789
[TBL] [Abstract][Full Text] [Related]
4. Gene therapy for canine alpha-L-iduronidase deficiency: in utero adoptive transfer of genetically corrected hematopoietic progenitors results in engraftment but not amelioration of disease.
Lutzko C; Omori F; Abrams-Ogg AC; Shull R; Li L; Lau K; Ruedy C; Nanji S; Gartley C; Dobson H; Foster R; Kruth S; Dubé ID
Hum Gene Ther; 1999 Jun; 10(9):1521-32. PubMed ID: 10395377
[TBL] [Abstract][Full Text] [Related]
5. Comparison of Endovascular and Intraventricular Gene Therapy With Adeno-Associated Virus-α-L-Iduronidase for Hurler Disease.
Janson CG; Romanova LG; Leone P; Nan Z; Belur L; McIvor RS; Low WC
Neurosurgery; 2014 Jan; 74(1):99-111. PubMed ID: 24077583
[TBL] [Abstract][Full Text] [Related]
6. Hematopoietic Stem Cell Gene Therapy Corrects Neuropathic Phenotype in Murine Model of Mucopolysaccharidosis Type II.
Wakabayashi T; Shimada Y; Akiyama K; Higuchi T; Fukuda T; Kobayashi H; Eto Y; Ida H; Ohashi T
Hum Gene Ther; 2015 Jun; 26(6):357-66. PubMed ID: 25761450
[TBL] [Abstract][Full Text] [Related]
7. Mucopolysaccharidosis type I.
Wraith JE; Jones S
Pediatr Endocrinol Rev; 2014 Sep; 12 Suppl 1():102-6. PubMed ID: 25345091
[TBL] [Abstract][Full Text] [Related]
8. Preclinical Testing of the Safety and Tolerability of Lentiviral Vector-Mediated Above-Normal Alpha-L-Iduronidase Expression in Murine and Human Hematopoietic Cells Using Toxicology and Biodistribution Good Laboratory Practice Studies.
Visigalli I; Delai S; Ferro F; Cecere F; Vezzoli M; Sanvito F; Chanut F; Benedicenti F; Spinozzi G; Wynn R; Calabria A; Naldini L; Montini E; Cristofori P; Biffi A
Hum Gene Ther; 2016 Oct; 27(10):813-829. PubMed ID: 27431943
[TBL] [Abstract][Full Text] [Related]
9. Hematopoietic Stem- and Progenitor-Cell Gene Therapy for Hurler Syndrome.
Gentner B; Tucci F; Galimberti S; Fumagalli F; De Pellegrin M; Silvani P; Camesasca C; Pontesilli S; Darin S; Ciotti F; Sarzana M; Consiglieri G; Filisetti C; Forni G; Passerini L; Tomasoni D; Cesana D; Calabria A; Spinozzi G; Cicalese MP; Calbi V; Migliavacca M; Barzaghi F; Ferrua F; Gallo V; Miglietta S; Zonari E; Cheruku PS; Forni C; Facchini M; Corti A; Gabaldo M; Zancan S; Gasperini S; Rovelli A; Boelens JJ; Jones SA; Wynn R; Baldoli C; Montini E; Gregori S; Ciceri F; Valsecchi MG; la Marca G; Parini R; Naldini L; Aiuti A; Bernardo ME;
N Engl J Med; 2021 Nov; 385(21):1929-1940. PubMed ID: 34788506
[TBL] [Abstract][Full Text] [Related]
10. Reprogramming erythroid cells for lysosomal enzyme production leads to visceral and CNS cross-correction in mice with Hurler syndrome.
Wang D; Zhang W; Kalfa TA; Grabowski G; Davies S; Malik P; Pan D
Proc Natl Acad Sci U S A; 2009 Nov; 106(47):19958-63. PubMed ID: 19903883
[TBL] [Abstract][Full Text] [Related]
11. Neonatal gene therapy of MPS I mice by intravenous injection of a lentiviral vector.
Kobayashi H; Carbonaro D; Pepper K; Petersen D; Ge S; Jackson H; Shimada H; Moats R; Kohn DB
Mol Ther; 2005 May; 11(5):776-89. PubMed ID: 15851016
[TBL] [Abstract][Full Text] [Related]
12. Neonatal bone marrow transplantation prevents bone pathology in a mouse model of mucopolysaccharidosis type I.
Pievani A; Azario I; Antolini L; Shimada T; Patel P; Remoli C; Rambaldi B; Valsecchi MG; Riminucci M; Biondi A; Tomatsu S; Serafini M
Blood; 2015 Mar; 125(10):1662-71. PubMed ID: 25298037
[TBL] [Abstract][Full Text] [Related]
13. Replacing the enzyme alpha-L-iduronidase at birth ameliorates symptoms in the brain and periphery of dogs with mucopolysaccharidosis type I.
Dierenfeld AD; McEntee MF; Vogler CA; Vite CH; Chen AH; Passage M; Le S; Shah S; Jens JK; Snella EM; Kline KL; Parkes JD; Ware WA; Moran LE; Fales-Williams AJ; Wengert JA; Whitley RD; Betts DM; Boal AM; Riedesel EA; Gross W; Ellinwood NM; Dickson PI
Sci Transl Med; 2010 Dec; 2(60):60ra89. PubMed ID: 21123810
[TBL] [Abstract][Full Text] [Related]
14. Direct gene transfer to the CNS prevents emergence of neurologic disease in a murine model of mucopolysaccharidosis type I.
Wolf DA; Lenander AW; Nan Z; Belur LR; Whitley CB; Gupta P; Low WC; McIvor RS
Neurobiol Dis; 2011 Jul; 43(1):123-33. PubMed ID: 21397026
[TBL] [Abstract][Full Text] [Related]
15. Neonatal combination therapy improves some of the clinical manifestations in the Mucopolysaccharidosis type I murine model.
Santi L; De Ponti G; Dina G; Pievani A; Corsi A; Riminucci M; Khan S; Sawamoto K; Antolini L; Gregori S; Annoni A; Biondi A; Quattrini A; Tomatsu S; Serafini M
Mol Genet Metab; 2020 Jul; 130(3):197-208. PubMed ID: 32439268
[TBL] [Abstract][Full Text] [Related]
16. Enzyme replacement therapy and/or hematopoietic stem cell transplantation at diagnosis in patients with mucopolysaccharidosis type I: results of a European consensus procedure.
de Ru MH; Boelens JJ; Das AM; Jones SA; van der Lee JH; Mahlaoui N; Mengel E; Offringa M; O'Meara A; Parini R; Rovelli A; Sykora KW; Valayannopoulos V; Vellodi A; Wynn RF; Wijburg FA
Orphanet J Rare Dis; 2011 Aug; 6():55. PubMed ID: 21831279
[TBL] [Abstract][Full Text] [Related]
17. Mucopolysaccharidosis Type I: Current Treatments, Limitations, and Prospects for Improvement.
Hampe CS; Wesley J; Lund TC; Orchard PJ; Polgreen LE; Eisengart JB; McLoon LK; Cureoglu S; Schachern P; McIvor RS
Biomolecules; 2021 Jan; 11(2):. PubMed ID: 33572941
[TBL] [Abstract][Full Text] [Related]
18. Intracerebroventricular transplantation of human bone marrow-derived multipotent progenitor cells in an immunodeficient mouse model of mucopolysaccharidosis type I (MPS-I).
Nan Z; Shekels L; Ryabinin O; Evavold C; Nelson MS; Khan SA; Deans RJ; Mays RW; Low WC; Gupta P
Cell Transplant; 2012; 21(7):1577-93. PubMed ID: 22472595
[TBL] [Abstract][Full Text] [Related]
19. Human genome-edited hematopoietic stem cells phenotypically correct Mucopolysaccharidosis type I.
Gomez-Ospina N; Scharenberg SG; Mostrel N; Bak RO; Mantri S; Quadros RM; Gurumurthy CB; Lee C; Bao G; Suarez CJ; Khan S; Sawamoto K; Tomatsu S; Raj N; Attardi LD; Aurelian L; Porteus MH
Nat Commun; 2019 Sep; 10(1):4045. PubMed ID: 31492863
[TBL] [Abstract][Full Text] [Related]
20. High-dose enzyme replacement therapy in murine Hurler syndrome.
Ou L; Herzog T; Koniar BL; Gunther R; Whitley CB
Mol Genet Metab; 2014 Feb; 111(2):116-22. PubMed ID: 24100243
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
